Pioglitazone-Induced Acute Rhabdomyolysis
| Autor: | Michel Biour, Chaker Ben Salem, Michele Zamy, Raoudha Slim |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Advanced and Specialized Nursing
medicine.medical_specialty medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Type 2 diabetes medicine.disease Gastroenterology Sulfonylurea Metformin Insulin resistance Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Online Letters: Observations Gliclazide business Acute rhabdomyolysis Pioglitazone medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc09-0593 |
| Popis: | Pioglitazone, a peroxisome proliferator–activated receptor γ agonist, is a relatively new oral antidiabetes agent. It has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations and A1C values. It can be used alone or in combination with metformin or a sulfonylurea. The adverse effects of pioglitazone include weight gain, headache, and edema. We report here a case of a patient who developed severe acute rhabdomyolysis after receiving pioglitazone. A 52-year-old man had a 2-year history of type 2 diabetes that was treated with gliclazide (60 mg/day). Six weeks after addition for pioglitazone (15 mg/day), the patient was admitted to hospital for 4 … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|